Journal article
EMBO Molecular Medicine, 2021
APA
Click to copy
Uhlitz, F., Bischoff, P., Peidli, S., Sieber, A., Trinks, A., Lüthen, M., … Morkel, M. (2021). Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Molecular Medicine.
Chicago/Turabian
Click to copy
Uhlitz, F., P. Bischoff, Stefan Peidli, A. Sieber, Alexandra Trinks, Mareen Lüthen, B. Obermayer, et al. “Mitogen‐Activated Protein Kinase Activity Drives Cell Trajectories in Colorectal Cancer.” EMBO Molecular Medicine (2021).
MLA
Click to copy
Uhlitz, F., et al. “Mitogen‐Activated Protein Kinase Activity Drives Cell Trajectories in Colorectal Cancer.” EMBO Molecular Medicine, 2021.
BibTeX Click to copy
@article{f2021a,
title = {Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer},
year = {2021},
journal = {EMBO Molecular Medicine},
author = {Uhlitz, F. and Bischoff, P. and Peidli, Stefan and Sieber, A. and Trinks, Alexandra and Lüthen, Mareen and Obermayer, B. and Blanc, E. and Ruchiy, Yana and Sell, Thomas and Mamlouk, S. and Arsiè, Roberto and Wei, Tzu-Ting and Klotz-Noack, Kathleen and Schwarz, R. and Sawitzki, B. and Kamphues, C. and Beule, D. and Landthaler, M. and Sers, C. and Horst, D. and Blüthgen, N. and Morkel, M.}
}
In colorectal cancer, oncogenic mutations transform a hierarchically organized and homeostatic epithelium into invasive cancer tissue lacking visible organization. We sought to define transcriptional states of colorectal cancer cells and signals controlling their development by performing single‐cell transcriptome analysis of tumors and matched non‐cancerous tissues of twelve colorectal cancer patients. We defined patient‐overarching colorectal cancer cell clusters characterized by differential activities of oncogenic signaling pathways such as mitogen‐activated protein kinase and oncogenic traits such as replication stress. RNA metabolic labeling and assessment of RNA velocity in patient‐derived organoids revealed developmental trajectories of colorectal cancer cells organized along a mitogen‐activated protein kinase activity gradient. This was in contrast to normal colon organoid cells developing along graded Wnt activity. Experimental targeting of EGFR‐BRAF‐MEK in cancer organoids affected signaling and gene expression contingent on predictive KRAS/BRAF mutations and induced cell plasticity overriding default developmental trajectories. Our results highlight directional cancer cell development as a driver of non‐genetic cancer cell heterogeneity and re‐routing of trajectories as a response to targeted therapy.